Evidence map›Paper›PMID 26351698›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells.

Gero Doose, Andrea Haake, Stephan H Bernhart, Cristina López, Sujitha Duggimpudi, Franziska Wojciech, Anke K Bergmann, Arndt Borkhardt, Birgit Burkhardt, Alexander Claviez and 32 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Transcriptome Study of 2 Black Cohorts RevealsJournal of the American Heart Association · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Vascular Regulation by Super Enhancer-Derived LINC00607.Frontiers in cardiovascular medicine · 2022
    Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

42 authors at 20 institutions in 3 countries.

Gero DooseTranscriptome Bioinformatics, Leipzig Research Center for Civilization Diseases, University of Leipzig, D-04107 Leipzig, Germany;
Andrea HaakeInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Stephan H BernhartTranscriptome Bioinformatics, Leipzig Research Center for Civilization Diseases, University of Leipzig, D-04107 Leipzig, Germany;
Cristina LópezInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Sujitha DuggimpudiDepartment of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Heinrich Heine University, Medical Faculty, D-40225 Düsseldorf, Germany;
Franziska WojciechInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Anke K BergmannInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany; Department of Pediatrics, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany;
Arndt BorkhardtDepartment of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Heinrich Heine University, Medical Faculty, D-40225 Düsseldorf, Germany;
Birgit BurkhardtDepartment of Pediatric Hematology and Oncology, University Hospital Münster, D-48149 Munster, Germany; Department of Pediatric Hematology and Oncology, University Hospital Giessen, D-35392 Giessen, Germany;
Alexander ClaviezDepartment of Pediatrics, University Hospital Schleswig-Holstein, D-24105 Kiel, Germany;
Lora DimitrovaInstitute of Pathology, Charité University Medicine Berlin, D-12200 Berlin, Germany;
Siegfried HaasFriedrich-Ebert Hospital Neumünster, Clinics for Hematology, Oncology and Nephrology, D-24534 Neumünster, Germany;
Jessica I HoellDepartment of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Heinrich Heine University, Medical Faculty, D-40225 Düsseldorf, Germany;
Michael HummelInstitute of Pathology, Charité University Medicine Berlin, D-12200 Berlin, Germany;
Dennis KarschDepartment of Internal Medicine II: Hematology and Oncology, University Medical Centre, D-24105 Kiel, Germany;
Wolfram KlapperHematopathology Section, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Karsten KleoInstitute of Pathology, Charité University Medicine Berlin, D-12200 Berlin, Germany;
Helene KretzmerTranscriptome Bioinformatics, Leipzig Research Center for Civilization Diseases, University of Leipzig, D-04107 Leipzig, Germany;
Markus KreuzInstitute for Medical Informatics Statistics and Epidemiology, University of Leipzig, D-04107 Leipzig, Germany;
Ralf KüppersInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, D-45122 Essen, Germany;
Chris LawerenzDivision Theoretical Bioinformatics, German Cancer Research Center, D-69120 Heidelberg, Germany;
Dido LenzeInstitute of Pathology, Charité University Medicine Berlin, D-12200 Berlin, Germany;
Markus LoefflerInstitute for Medical Informatics Statistics and Epidemiology, University of Leipzig, D-04107 Leipzig, Germany;
Luisa Mantovani-LöfflerHospital of Internal Medicine II, Hematology and Oncology, St. Georg Hospital Leipzig, D-04129 Leipzig, Germany;
Peter MöllerInstitute of Pathology, Ulm University, D-89070 Ulm, Germany;
German OttDepartment of Clinical Pathology, Robert Bosch Hospital and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, D-70376 Stuttgart, Germany;
Julia RichterInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Marius RohdeDepartment of Pediatric Hematology and Oncology, University Hospital Giessen, D-35392 Giessen, Germany;
Philip RosenstielInstitute of Clinical Molecular Biology, Christian Albrechts University, D-24105 Kiel, Germany;
Andreas RosenwaldInstitute of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, D-97080 Würzburg, Germany;
Markus SchilhabelInstitute of Clinical Molecular Biology, Christian Albrechts University, D-24105 Kiel, Germany;
Markus SchneiderInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, D-45122 Essen, Germany;
Ingrid ScholzDivision Theoretical Bioinformatics, German Cancer Research Center, D-69120 Heidelberg, Germany;
Stephan StilgenbauerDepartment of Internal Medicine III, University of Ulm, D-89081 Ulm, Germany;
Hendrik G StunnenbergDepartment of Molecular Biology, Radboud Institute for Molecular Life Sciences, Radboud University, 6525 Nijmegen, The Netherlands;
Monika SzczepanowskiHematopathology Section, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Lorenz TrümperDepartment of Hematology and Oncology, Georg August University of Göttingen, D-37075 Göttingen, Germany;
Marc A WenigerInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, D-45122 Essen, Germany;
ICGC MMML-Seq Consortium
Steve HoffmannTranscriptome Bioinformatics, Leipzig Research Center for Civilization Diseases, University of Leipzig, D-04107 Leipzig, Germany;
Reiner SiebertInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany;
Ingram IaccarinoInstitute of Human Genetics, University Hospital Schleswig-Holstein, Christian Albrechts University, D-24105 Kiel, Germany; Institute of Genetics and Biophysics "A.Buzzati-Traverso," Consiglio Nazionale delle Ricerche, I-80131 Naples, Italy iiaccarino@medgen.uni-kiel.de.
University Hospital Schleswig-Holstein · DEKiel University · DELeipzig University · DEGerman Cancer Research Center · DEUniversity of Lübeck · DEUniversity Hospital Münster · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DEUniversity of Duisburg-Essen · DEUniversity of Göttingen · DEFriedrich-Ebert-Krankenhaus · DEHeinrich Heine University Düsseldorf · DEUniversitätsklinikum Gießen und Marburg · DEUniversität Ulm · DEClinical Research Center Kiel · DEDüsseldorf University Hospital · DEUniversity of Würzburg · DEComprehensive Cancer Center Mainfranken · DEGoethe University Frankfurt · DEKlinikum St. Georg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the established role of the transcription factor MYC in cancer, little is known about the impact of a new class of transcriptional regulators, the long noncoding RNAs (lncRNAs), on MYC ability to influence the cellular transcriptome. Here, we have intersected RNA-sequencing data from two MYC-inducible cell lines and a cohort of 91 B-cell lymphomas with or without genetic variants resulting in MYC overexpression. We identified 13 lncRNAs differentially expressed in IG-MYC-positive Burkitt lymphoma and regulated in the same direction by MYC in the model cell lines. Among them, we focused on a lncRNA that we named MYC-induced long noncoding RNA (MINCR), showing a strong correlation with MYC expression in MYC-positive lymphomas. To understand its cellular role, we performed RNAi and found that MINCR knockdown is associated with an impairment in cell cycle progression. Differential gene expression analysis after RNAi showed a significant enrichment of cell cycle genes among the genes down-regulated after MINCR knockdown. Interestingly, these genes are enriched in MYC binding sites in their promoters, suggesting that MINCR acts as a modulator of the MYC transcriptional program. Accordingly, MINCR knockdown was associated with a reduction in MYC binding to the promoters of selected cell cycle genes. Finally, we show that down-regulation of Aurora kinases A and B and chromatin licensing and DNA replication factor 1 may explain the reduction in cellular proliferation observed on MINCR knockdown. We, therefore, suggest that MINCR is a newly identified player in the MYC transcriptional network able to control the expression of cell cycle genes.

Indexed as

Gene Expression Regulation, NeoplasticGene Regulatory NetworksBase SequenceBinding SitesBurkitt LymphomaCell CycleCell LineCell Line, TumorCell SurvivalChromatinGene Expression ProfilingHumansIn Situ Hybridization, FluorescenceLymphoma, B-CellMolecular Sequence DataNeoplasmsChromatinlong non-coding RNA MINCR, humanProto-Oncogene Proteins c-mycRNA, Long NoncodingRNA, Small InterferingB-cell lymphomacell cyclelncRNAMYC

Identifiers

PMID26351698
PMCPMC4586867
OpenAlexW2129086022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.